CIA
PCVX icon

Cape Investment Advisory’s Vaxcyte PCVX Stock Holding History

Cape Investment Advisory’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26
Closed -$937 – 1329
2025
Q3 		$937 Hold
26
– – ﹤0.01% 744
2025
Q2 		$845 Buy
+26
New +$852 ﹤0.01% 1049

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cape Investment Advisory's PCVX Position: Q4 2025 in Review

Cape Investment Advisory sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 26 shares — an estimated $937 sold.

Cape Investment Advisory first reported a position in PCVX in Q2 2025 and held it in 2 quarters. The position peaked at $937 in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Cape Investment Advisory reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Cape Investment Advisory sold 26 Vaxcyte shares in Q4 2025, an estimated $937.
  • Cape Investment Advisory first reported a position in Vaxcyte in Q2 2025 and held it in 2 quarters.
  • Cape Investment Advisory's Vaxcyte position peaked at $937 in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Cape Investment Advisory's 13F filing for Q4 2025, filed 17 Feb 2026.